Patent · US Active

Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction

US9822355B2 · kind B2 · utility

6Cited by

2References

14Claims

0Family size

Assignee

Children's Medical Center Corporation · US

Inventors

Stuart H. Orkin · Brookline, US
Daniel E. Bauer · Cambridge, US
Jian Xu · Beijing, CN

Key dates

Filing date	Nov 27, 2013
Grant date	Nov 21, 2017
Priority date	—
Expiry date	Nov 27, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N15/63
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods and compositions for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.